TITLE

Skin lesions in a 30-year-old male having smear-positive pulmonary tuberculosis

AUTHOR(S)
Gupta, Prem P.; Jain, V. K.; Agarwal, Dipti; Yaseer, P. T.
PUB. DATE
January 2009
SOURCE
Annals of Thoracic Medicine;Jan2009, Vol. 4 Issue 1, p32
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a 30-year-old male patient, who presented with low-grade intermittent fever, cough with expectoration and asymptomatic, painless, dusky red skin lesions, and was diagnosed with smear-positive pulmonary tuberculosis (TB). It notes that the patient was treated with rifampicin, isoniazid, pyrazinamide and ethambutol for two months, by the end of which his sputum changed to negative. A survey from dermatology clinics in Hong Kong, China states that the incidence of cutaneous TB was 179 per 267,089 patients.
ACCESSION #
36183878

 

Related Articles

  • Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana. Chideya, Sekai; Winston, Carla A.; Peloquin, Charles A.; Bradford, William Z.; Hopewell, Philip C.; Wells, Charles D.; Reingold, Arthur L.; Kenyon, Thomas A.; Moeti, Themba L.; Tappero, Jordan W. // Clinical Infectious Diseases;6/15/2009, Vol. 48 Issue 12, p1685 

    Background. We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis in Botswana. Methods. Consenting outpatients with tuberculosis had blood samples collected 1, 2, and 6 h after simultaneous isoniazid,...

  • Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. Zvada, Simbarashe P.; Denti, Paolo; Donald, Peter R.; Schaaf, H. Simon; Thee, Stephanie; Seddon, James A.; Seifart, Heiner I.; Smith, Peter J.; McIlleron, Helen M.; Simonsson, Ulrika S. H. // Journal of Antimicrobial Chemotherapy (JAC);May2014, Vol. 69 Issue 5, p1339 

    Objectives To describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children and evaluate the adequacy of steady-state exposures. Patients and methods We used previously published data for 76 South African children with tuberculosis to describe the population...

  • Pyrazinamide increases the risk of liver injury.  // Reactions Weekly;7/26/2008, Issue 1212, p4 

    The article discusses research being done on pyrazinamide. It references a study by K. C. Chang and colleagues published in the June 15, 2008 issue of the "American Journal of Respiratory and Critical Care Medicine." The results from a cohort and nested-case control analysis revealed that the...

  • Rifampicin/isoniazid/pyrazinamide.  // Reactions Weekly;Nov2014, Vol. 1524 Issue 1, p167 

    The article discusses a case study of a 63-year-old man who developed dysosmia following the administration of isniazid/rifampicin/pyrazinamide (Rifater) for the treatment of pulmonary tuberculosis.

  • Study of Stability of New Mutual Prodrugs with Antimycobacterial Activity. Jampilek, Josef; Reckova, Zuzana; Imramovsky, Ales; Raich, Ivan; Vinsova, Jarmila; Dohnal, Jiri // Current Organic Chemistry;May2008, Vol. 12 Issue 8, p667 

    New mutual prodrugs of pyrazinamide, isoniazid, p-aminosalicylic acid and ciprofloxacine were designed and synthesised. All the prepared compounds were tested for their antimycobacterial activities. Several discussed compounds showed excellent biological effects against both Mycobacterium...

  • The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Somoskovi, Akos; Parsons, Linda M.; Salfinger, Max // Respiratory Research;2001, Vol. 2, p164 

    Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an...

  • Isoniazid/pyrazinamide/rifampicin.  // Reactions Weekly;Apr2015, Vol. 1545 Issue 1, p144 

    The article discusses a study published in the 2014 issue of "Clinical and Translational Allergy" that presented a 10-year-old boy who developed various toxicities following administration of isoniazid, rifampicin and pyrazinamide.

  • Rifampicin/isoniazid/pyrazinamide.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p80 

    The article describes the case of an 83-year-old man who experienced an allergic reaction after receiving rifampicin/isoniazid/pyrazinamide. The patient had a pacemaker and a history of hypertension and asthma. Particular focus is given to his dosing regimen and the results of intradermal...

  • Latent tuberculosis infection. Sivaraman, Priya; Gianakos, Dean G. // Patient Care;Aug2004, Vol. 38 Issue 8, p13 

    Presents the case of a 32-year-old male who was diagnosed with latent tuberculosis infection. Outcome of a purified protein derivative test undergone by the patient; Methods used in risk stratification for tuberculosis testing; Variables measured by the QuantiFERON test; Treatment regimens for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics